Cargando…
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort
BACKGROUND: The hepatitis C virus (HCV) infects nearly 3% of the World's population, causing severe liver disease in many. Standard of care therapy is currently pegylated interferon alpha and ribavirin (PegIFN/R), which is effective in less than half of those infected with the most common viral...
Autores principales: | Smith, Katherine R, Suppiah, Vijayaprakash, O'Connor, Kate, Berg, Thomas, Weltman, Martin, Abate, Maria Lorena, Spengler, Ulrich, Bassendine, Margaret, Matthews, Gail, Irving, William L, Powell, Elizabeth, Riordan, Stephen, Ahlenstiel, Golo, Stewart, Graeme J, Bahlo, Melanie, George, Jacob, Booth, David R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238183/ https://www.ncbi.nlm.nih.gov/pubmed/21884576 http://dx.doi.org/10.1186/gm273 |
Ejemplares similares
-
IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study
por: Suppiah, Vijayaprakash, et al.
Publicado: (2011) -
Zinc is a potent and specific inhibitor of IFN-λ3 signalling
por: Read, Scott A., et al.
Publicado: (2017) -
Haplotype analysis of APOE intragenic SNPs
por: Babenko, Vladimir N., et al.
Publicado: (2018) -
Pharmacogenomics of hepatitis C infections: personalizing therapy
por: Booth, David R, et al.
Publicado: (2012) -
The Natural Killer Cell Response to HCV Infection
por: Ahlenstiel, Golo
Publicado: (2013)